Get Live Data

We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

  2. Share Prices
  3. Hutchmed Share Price
  4. Hutchmed Share Regulatory News

Pin to quick picksHutchmed Regulatory News (HCM)

Hutchmed Information

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 289.00
Ask: 293.00
Change: -14.00 (-4.61%)
Spread: 4.00 (1.384%)
Open: 312.00
High: 312.00
Low: 287.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

12345678910
Date   Source Headline
12th May 20231:15 pmRNSAnnual General Meeting Poll Results
12th May 20239:30 amRNSBoard of Directors and Board Committee Membership
10th May 20239:30 amRNSAppointment of Independent NED
28th Apr 20239:30 amRNSTotal Voting Rights
21st Apr 20239:30 amRNSVesting of awards under the LTIP
18th Apr 20237:00 amRNSNDA Acceptance in China for Fruquintinib
12th Apr 20237:00 amRNSPresentations at AACR Annual Meeting 2023
11th Apr 20239:30 amRNSIntended Retirement of Independent NED
11th Apr 20239:30 amRNS2022 Annual Report and Notice of AGM
4th Apr 202310:30 amRNSHUTCHMED Initiates Registration Phase Enrollments
31st Mar 20239:30 amRNSTotal Voting Rights
31st Mar 20237:00 amRNSRolling Submission of Fruquintinib US NDA Complete
14th Mar 20231:30 pmRNSClosing of Fruquintinib License to Takeda
8th Mar 20238:30 amRNSDirector's Share Dealing
6th Mar 20238:30 amRNSVesting of awards under the LTIP
28th Feb 202312:15 pmRNSPublication of Form 20-F
28th Feb 20238:30 amRNS2022 Full Year Results and Business Updates
27th Feb 202310:00 amRNSEnrollment Completed in Phase 2 Amdizalisib trial
31st Jan 20238:30 amRNSNotice of Results
23rd Jan 20238:00 amRNSLicense to Takeda for Fruquintinib outside China
18th Jan 20232:30 pmRNSInclusion of ORPATHYS in NRDL in China
3rd Jan 20238:30 amRNSEnrollment Completed in Phase 3 Trial
30th Dec 20228:30 amRNSBlocklisting Six Monthly Return
19th Dec 202210:00 amRNSFDA NDA Rolling Submission for Fruquintinib
15th Nov 20227:00 amRNSHUTCHMED Announces Strategy Update
14th Nov 20227:00 amRNSPositive Topline Phase 3 Result in Fruquintinib
27th Oct 202212:30 pmRNSHUTCHMED Initiates Phase 2/3 Trial of Fruquintinib
21st Oct 20229:30 amRNSVesting of awards under the LTIP
10th Oct 20229:30 amRNSPhase II/III Trial of Sovleplenib for in China
30th Sep 20229:30 amRNSTotal Voting Rights
14th Sep 202211:00 amRNSShare Option Scheme and Long Term Incentive Plan
8th Sep 20227:00 amRNSFRESCO-2 Colorectal Cancer MRCT Data Highlights
23rd Aug 202210:00 amRNSHolding(s) in Company
23rd Aug 20229:30 amRNSHUTCHMED To Present FRESCO-2 Data at ESMO 2022
9th Aug 20229:30 amRNSFirst Participant in Phase I Trial of IMG-004
8th Aug 20229:30 amRNSPreliminary results from SAVANNAH Phase 2 Trial
8th Aug 20227:00 amRNSFRESCO-2 Study Has Met Primary Endpoint
1st Aug 202212:04 pmRNSInterim Results and Business Updates
1st Aug 20227:00 amRNSHUTCHMED Initiates Bridging Study of Tazemetostat
15th Jul 20229:30 amRNSHUTCHMED Initiates Phase I Trial of HMPL-A83
13th Jul 20227:00 amRNSResults of SAVANNAH Global Phase II Trial at WCLC
6th Jul 20227:00 amRNSFirst Participants in Phase I Trial of IMG-007
30th Jun 20229:30 amRNSTotal Voting Rights
29th Jun 20229:30 amRNSBlocklisting Six Monthly Return
27th Jun 20229:30 amRNSHUTCHMED to Announce 2022 Half-Year Results
1st Jun 20229:30 amRNSTAZVERIK® Approved in Hainan Pilot Zone
24th May 202211:00 amRNSLTIP and Share Options
16th May 202212:00 pmRNSAppointment of Non–Executive Director
3rd May 20227:00 amRNSHUTCHMED Receives CRL from the US FDA
27th Apr 20222:30 pmRNSAnnual General Meeting Poll Results
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.